中国脑血管病杂志2025，Vol.22Issue(2)：127-134,8.DOI:10.3969/j.issn.1672-5921.2025.02.009
替奈普酶治疗急性缺血性卒中的研究进展
Research progress of tenecteplase in acute ischemic stroke
摘要
Abstract
Tenecteplase is a third-generation thrombolytic drug.Compared with alteplase,it has the advantages of longer half-life and higher fibrin specificity.The effectiveness and safety of tenecteplase in the treatment of acute ischemic stroke have been extensively studied in clinical research.The article summarized the research progress of tenecteplase in the treatment of acute ischemic stroke based on completed randomized controlled studies and related Meta-analyses,and explored the pharmacological characteristics,effectiveness,and safety of tenecteplase,as well as current guideline recommendations,aiming to offer a reference for choosing more appropriate diagnostic and therapeutic methods for patients with acute ischemic stroke.关键词
替奈普酶/缺血性卒中/桥接治疗/静脉溶栓/综述Key words
Tenecteplase/Ischemic stroke/Bridging therapy/Intravenous thrombolysis/Review引用本文复制引用
卓娜,樊宇,赵美丽,王璐,张菊林..替奈普酶治疗急性缺血性卒中的研究进展[J].中国脑血管病杂志,2025,22(2):127-134,8.基金项目
内蒙古自治区科技创新引导项目(CXYD2022BT02) （CXYD2022BT02）
内蒙古自治区科技计划项目(2021GG0223) （2021GG0223）
